Comparative Pharmacology
Head-to-head clinical analysis: EXONDYS 51 versus VILTEPSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXONDYS 51 versus VILTEPSO.
EXONDYS 51 vs VILTEPSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antisense oligonucleotide that binds to exon 51 of dystrophin pre-mRNA, inducing skipping of exon 51 during splicing to restore the reading frame and produce a truncated but functional dystrophin protein in patients with Duchenne muscular dystrophy (DMD) who have confirmed mutations amenable to exon 51 skipping.
Antisense oligonucleotide that binds to exon 51 of dystrophin pre-mRNA, excluding it during splicing to restore the reading frame and produce a truncated but functional dystrophin protein in patients with Duchenne muscular dystrophy (DMD) with confirmed mutations amenable to exon 51 skipping.
30 mg/kg intravenously over 35-60 minutes once weekly
30 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 28-32 days. This long half-life supports weekly dosing intervals.
The terminal elimination half-life is approximately 3-4 weeks in plasma, reflecting slow clearance due to tissue binding and prolonged intracellular retention. Clinically, this supports weekly intravenous dosing.
Primarily eliminated via renal excretion as intact oligonucleotide. Approximately 30-40% of administered dose is excreted unchanged in urine within 24 hours. No significant biliary or fecal elimination.
Viltepso is primarily eliminated via renal excretion. Approximately 60-70% of the administered dose is excreted unchanged in urine within 24 hours, with minimal biliary/fecal elimination (less than 5%).
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide